Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-416-5950627
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$34,000.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
Trillium Therapeutics (TSE:TRIL) Frequently Asked Questions
What is Trillium Therapeutics' stock symbol?
Trillium Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRIL."
What is the consensus analysts' recommendation for Trillium Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trillium Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Trillium Therapeutics.
Has Trillium Therapeutics been receiving favorable news coverage?
Media coverage about TRIL stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Trillium Therapeutics earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Trillium Therapeutics.
Who are some of Trillium Therapeutics' key competitors?
Some companies that are related to Trillium Therapeutics include Exopharm (EX1), Nuformix (NFX), Rhinomed (RNO), Armata Pharmaceuticals (ARMP), Pharmaust (PAA), Actinium Pharmaceuticals (ATNM), Medicenna Therapeutics (MDNA), Immunoprecise Antibodies (IPA), Tissue Regenix Group (TRX), Actinium Pharmaceuticals (ATNM), Altimmune (ALT), Ixico (IXI), Acrux (ACR), Kazia Therapeutics (KZA) and Biocardia (BCDA).
What other stocks do shareholders of Trillium Therapeutics own?
Who are Trillium Therapeutics' key executives?
Trillium Therapeutics' management team includes the folowing people:
- Dr. Bjorn Johan Niclas Stiernholm, Pres, CEO & Director
- Mr. James T. Parsons C.A., C.P.A., MAcc, CPA-CA, Chief Financial Officer (Age 54)
- Dr. Robert Uger, Chief Scientific Officer
- Dr. Penka Petrova, Chief Devel. Officer
- Dr. Yaping Shou, Chief Medical Officer
How do I buy shares of Trillium Therapeutics?
Shares of TRIL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
How big of a company is Trillium Therapeutics?
What is Trillium Therapeutics' official website?
How can I contact Trillium Therapeutics?
Trillium Therapeutics' mailing address is 2488 Dunwin Dr, MISSISSAUGA, ON L5L 1J9, Canada. The company can be reached via phone at +1-416-5950627.
MarketBeat Community Rating for Trillium Therapeutics (TSE TRIL)
MarketBeat's community ratings are surveys of what our community members think about Trillium Therapeutics and other stocks. Vote "Outperform" if you believe TRIL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRIL will underperform the S&P 500 over the long term. You may vote once every thirty days.
